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Abstract
Human immunodeficiency virus type 1 (HIV-1) coreceptor usage and tropism can be modulated
by the V3 loop sequence of the gp120 exterior envelope glycoprotein. For coreceptors, R5 viruses
use CCR5, X4 viruses use CXCR4, and dual-tropic (R5X4) viruses use either CCR5 or CXCR4.
To understand the requirements for dual tropism, we derived and analyzed a dual-tropic variant of
an X4 virus. Changes in the V3 base, which allow gp120 to interact with the tyrosine-sulfated
CCR5 N-terminus, and deletion of residues 310/311 in the V3 tip were necessary for efficient
CCR5 binding and utilization. Thus, both sets of V3 changes allowed CCR5 utilization with
retention of the ability to use CXCR4. We also found that the stable association of gp120 with the
trimeric envelope glycoprotein complex in R5X4 viruses, as in X4 viruses, is less sensitive to V3
loop changes than gp120-trimer association in R5 viruses.
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Introduction
The entry of human immunodeficiency virus type 1 (HIV-1) into the host cell is mediated by
the viral envelope glycoproteins (Choe et al., 1998; Wyatt and Sodroski, 1998). The
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envelope glycoproteins, gp120 (SU) and gp41 (TM), constitute a trimeric complex that is
anchored on the virion surface by the membrane-spanning segments of gp41 (Chan et al.,
1997; Farzan et al., 1998; Weissenhorn et al., 1997; Zhu et al., 2003). The mature envelope
glycoproteins form a trimer in which three gp120 subunits are noncovalently bound to three
membrane-anchored gp41 subunits (Helseth et al., 1991). The initial binding of gp120 to the
cellular receptor CD4 triggers conformational changes in gp120 that allow the subsequent
interaction with one of the chemokine coreceptors, usually CCR5 or CXCR4 (Alkhatib et
al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng
et al., 1996; Wu et al., 1996). Coreceptor binding is thought to induce additional
conformational changes in the envelope glycoproteins that lead to the fusion of the viral and
target cell membrane (Hoffman and Doms, 1999).
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HIV-1 can be classified into three phenotypes based on the virus' ability to use the CCR5
and/or CXCR4 coreceptor (Berger et al., 1998). R5 viruses use CCR5 as the coreceptor, X4
viruses use CXCR4 as the coreceptor and R5X4 (dual-tropic) viruses can use both
coreceptors. HIV-1 primarily infects human CD4-positive T cells and macrophages. Cellular
tropism can be determined by coreceptor usage (Rana et al., 1997). R5 viruses infect
primary macrophages and T lymphocytes, whereas X4 viruses infect primary T lymphocytes
and T-cell lines (Rana et al., 1997). The coreceptor usage, and thus, cellular tropism, is
mainly determined by the third variable loop (V3 loop) of the gp120 exterior envelope
glycoprotein (Chavda et al., 1994; Chesebro et al., 1996; Hwang et al., 1991).
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The V3 loop of HIV-1 gp120 is about 34–37 residues in length but exhibits significant
variability among different isolates (Hartley et al., 2005). Structurally, the V3 loop can be
divided into three regions: the base, the stem and the tip (crown) (Huang et al., 2005). The
V3 stem is more variable in sequence, whereas the base and tip are relatively conserved.
Because the V3 loop is the main determinant of coreceptor usage (Chesebro et al., 1996;
Hoffman et al., 2002; Shioda, Levy, and Cheng-Mayer, 1992; Willey, Theodore, and Martin,
1994), it has been intensively studied for the purposes of understanding interactions with the
coreceptors and predicting coreceptor usage of HIV-1 isolates. In general, the V3 loops of
X4 viruses have a greater number of positive charges than those of R5 viruses (Jensen et al.,
2003; Low et al., 2007); however, distinct sequence characteristics have not been defined for
the V3 loops of dual-tropic viruses. Some studies have shown that residues 306, 321 and
322, the N-linked glycan at residue 301, and the total number of positive charges in the V3
loop are important for determining coreceptor preference (Cardozo et al., 2007; de Jong et
al., 1992; Fouchier et al., 1995; Ogert et al., 2001; Polzer et al., 2002). In addition, some
bioinformatics tools have been developed to predict coreceptor usage (Chueca et al., 2009;
Jensen et al., 2003). However, the prediction of coreceptor usage for a given V3 loop based
only on the V3 amino acid sequence is still imperfect.
In this report, we explore in more detail the interactions between the V3 loop sequences and
coreceptors CCR5 and CXCR4. We identify an interesting derivative of the prototypic X4
strain, HXBc2, that has acquired the ability to use CCR5 but still retains CXCR4 usage.
Two residues in the base of the V3 loop were found to be critical for this dual-tropic
phenotype. Modeling based on available x-ray crystal and NMR structures and mutagenesis
data suggest that these residues contact the tyrosine-sulfated N-terminus of the chemokine
receptor. Another pair of HXBc2 amino acid residues at the tip of the V3 loop was found to
be detrimental to CCR5 binding and had to be deleted to allow CCR5 tropism. In addition to
analyzing the effects of these changes on HIV-1 tropism, we examined the impact of the V3
changes on envelope glycoprotein trimer stability and discovered that R5X4 and X4 HIV-1
exhibit similar phenotypes that are distinct from those of R5 HIV-1.
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Results
Generation of a dual-tropic HXBc2 variant
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We wished to study the specific role of certain residues in the gp120 V3 loop that are
important for coreceptor interaction, with the aim of understanding the mechanism by which
some HIV-1 viruses acquire dual tropism. Figure 1 shows an alignment of the V3 loops of
some common X4-, R5-, and dual-tropic viruses. Most natural HIV-1 isolates lack residues
310–311 (QR in some laboratory-adapted X4-tropic viruses). Residues 325 and 326 (NM in
the laboratory-adapted X4-tropic viruses) are more commonly DI in primary R5 or R5X4
HIV-1 strains, suggesting that these residues could be important for CCR5 interaction.
Previous studies have shown the importance of some of these motifs in virus tropism (Hung,
Vander Heyden, and Ratner, 1999); however, the exact mechanism by which these changes
affect viral phenotypes has not been defined. To investigate the contribution of these
residues to coreceptor choice, we generated HXBc2 mutants containing a deletion in
residues 310–311 (ΔQR) and/or the changes N325D/M326I (DI) (Figure 2A). The
infectivity of these V3 loop mutants was analyzed in Cf2Th cells expressing CD4 and either
CXCR4 or CCR5. Corroborating the hypothesized role of these residues in coreceptor
usage, we observed that, like the R5-tropic ADA virus and the dual-tropic 89.6 virus, the
DIΔQR mutant was able to infect Cf2Th cells expressing CD4 and CCR5 efficiently (Figure
2B). Surprisingly, the DIΔQR mutant retained the ability to infect CD4/CXCR4 cells
efficiently and thus exhibited dual tropism.
To characterize further the contribution of the two V3 elements to tropism, we generated
HXBc2 viruses containing only the DI substitutions (DI) or the QR deletion (ΔQR). When
these changes were individually introduced, the resulting mutant viruses were unable to
mediate entry of HIV-1 into CD4/CCR5 cells. In addition, their infectivity in CD4/CXCR4
cells was reduced compared to that of the wild-type HXBc2 (27% and 68% for the DI and
ΔQR mutants, respectively) (Figure 2B). The substitution of an alanine residue for Arg 311
in the context of the DI mutant (DI/R311A) abolished the infectivity in CD4/CCR5 and in
CD4/CXCR4 cells (Figure 2B). By contrast, changing Arg 306 to Ser did not alter
coreceptor usage in the context of either HXBc2 or the DI mutant (Figure 2B). Together,
these data suggest that both the ΔQR and DI changes in the V3 region are necessary for the
dual-tropic phenotype.
Binding of DIΔQR mutants to the 412d antibody and CCR5
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The 412d monoclonal antibody mimics the tyrosine sulfate-containing N-terminus of the
CCR5 coreceptor (Choe et al., 2003; Huang et al., 2007; Xiang et al., 2005). To assess the
binding of the V3 loop mutants to the 412d antibody, cell supernatants containing
radiolabeled gp120 glycoproteins were immunoprecipitated with 412d and the bound gp120
was analyzed on an SDS-PAGE gel. As expected, the wild-type HXBc2 gp120 and the X4
ΔQR and R306S mutants did not efficiently bind the 412d antibody (Figure 2C). However,
412d was able to bind and immunoprecipitate the R5X4 DIΔQR mutant. Surprisingly, 412d
also recognized the DI and DI/R306S mutants (Figure 2C), even though these two mutants
were not able to infect CD4/CCR5 cells. Similar results were obtained when the DI change
was introduced into the gp120 glycoprotein of another X4 virus, NL4-3 (Figure 2C). These
results indicate that the DI change, but not the ΔQR deletion, is required for 412d antibody
binding.
The binding of the V3 loop mutants to CCR5 was also studied. Supernatants from cells
expressing radiolabeled gp120 were incubated, in the presence of soluble CD4, with cells
expressing CCR5. The bound gp120 glycoprotein was analyzed by SDS-PAGE. In contrast
with the 412d binding results, when we tested the DI and DI/R306S mutants for their ability
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Membrane fusion ability of the DIΔQR mutant
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to bind CCR5, we observed that the DI change alone was not sufficient to allow binding to
CCR5 (data not shown); only the DIΔQR mutant was able to bind CCR5 detectably (Figure
2D). Apparently, the DI change is sufficient to allow binding to 412d and perhaps, by
analogy, with the tyrosine-sulfated CCR5 N-terminus; however, other changes, specifically
the removal of the QR residues in the V3 tip, are required for binding to the intact CCR5
coreceptor. These binding results explain why only the DIΔQR mutant, but not the DI
mutant, is able to infect CD4/CCR5-expressing cells.

The DI motif in the C-terminal region of the V3 loop is necessary for CCR5 usage

The ability of the V3 loop mutants to mediate the fusion of envelope glycoproteinexpressing cells and cells bearing CD4 and either CCR5 or CXCR4 was assessed using the
α-complementation assay (Holland et al., 2004). 293T cells were cotransfected with
plasmids expressing the mutant envelope glycoproteins and the α-fragment of βgalactosidase. The cotransfected 293T cells were cocultivated with canine Cf2Th cells
expressing CD4, one of the coreceptors CCR5 or CXCR4, and the ω fragment of βgalactosidase. The fusion of the envelope-expressing 293T cells with the Cf2Th cells
expressing HIV-1 receptors results in the reconstitution of enzymatically active βgalactosidase. The measurement of β-galactosidase activity provides a quantification of the
extent of the fusion. The membrane fusion data (Figure 3) showed that all the mutants
assayed, DI, ΔQR, R306S, DI/R306S and DIΔQR, retained the ability to fuse with CD4/
CXCR4-expressing cells at levels comparable to that of the wild-type HXBc2 envelope
glycoproteins. Only the DIΔQR mutant gained the ability to fuse with CD4/CCR5expressing cells at levels comparable to that of the envelope glycoproteins of the dual-tropic
virus 89.6. Thus, the results of the cell-cell fusion assay agree with the infectivity and
CCR5-binding data (Figure 2).

NIH-PA Author Manuscript

The above results indicated that, in the context of HXBc2 envelope glycoprotein, the DI
motif (residues 325–326) in the C-terminal segment of the V3 loop is important for CCR5
usage and binding (Figure 2B and 2D), as well as sufficient for 412d binding (Figure 2C).
Thus, we further dissected this motif by making single alanine substitutions in residues 325
and 326 of the DIΔQR mutant (Figure 2A). The binding of the resulting mutants, DIΔQR
D325A and DIΔQR I326A, to the 412d antibody was significantly reduced or abolished,
respectively (Figure 4A). We also tested the binding of these mutants to a mixture of
polyclonal sera from HIV-1-infected individuals and monoclonal antibodies E51, a CD4induced antibody, and F425b, an antibody that specifically binds to the V3 loop of R5
viruses (Cavacini et al., 2003; Xiang et al., 2003). The 412d and F425b antibodies
precipitated the R5 ADA gp120 but not the X4 HXBc2 gp120, as expected. Both DIΔQR
mutants were recognized by the E51 and F425b antibodies; the DIΔQR D325A and DIΔQR
I326A mutants were precipitated slightly less efficiently than DIΔQR by the E51 antibody
(Figure 4A). Both mutant envelope glycoproteins were processed at levels comparable to
wild-type HXBc2 and ADA envelopes (Figure 4B). The ratio of gp120 shed into the
medium relative to the cell-associated gp120 was similar to that of the wild-type
glycoproteins for all the mutants (Figure 4B). These results together indicate that the
reduced binding to 412d was not due to a global misfolding of the mutant envelope
glycoproteins, and that aspartic acid 325 and isoleucine 326 are important for the
recognition of gp120 by the 412d antibody.
The infectivity of the D325A and I326A mutants was assessed in Cf2Th cell lines
expressing the HIV-1 receptors. Both mutants infected CD4/CXCR4 cells efficiently (Figure
4C), suggesting that these mutant envelope glycoproteins are properly folded and functional
for CXCR4 binding. However, the D325A and I326A changes resulted in a loss of the
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ability of the DIΔQR mutant to infect CD4/CCR5 cells (Figure 4C). These results support
the importance of the DI motif for CCR5 coreceptor usage, but not for CXCR4 usage.
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Asparagine 302 in the V3 N-terminus contributes to CCR5 binding
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In the N-terminal segment of the V3 loop there is a motif of three asparagines (NNN) that is
relatively well conserved among most HIV-1 strains (Figure 1). This motif lies in the base of
the V3 loop in close proximity to residues 325–326 (Huang et al., 2007; Schnur et al., 2011).
We investigated the importance of this region to CCR5 and CXCR4 usage by changing Asn
302 to aspartic acid; this change does not delete the potential N-linked glycosylation site at
Asn 301. Introduction of an N302D change in the context of the DIΔQR envelope
glycoprotein drastically reduced the binding of gp120 to the 412d antibody (Figure 4A), as
was seen for the D325A and I326A mutants. The DIΔQR N302D mutant was recognized
efficiently by the E51 and F425b monoclonal antibodies. To confirm whether the N302D
change would affect the coreceptor usage of the DIΔQR virus, we tested the ability of this
mutant to infect cells expressing CD4 and either CCR5 or CXCR4. The expression,
processing and subunit association of the DIΔQR N302D mutant were comparable to those
of the wild-type HXBc2 envelope glycoproteins and the DIΔQR mutant (Figure 4B).
However, the N302D change abolished the ability of the DIΔQR envelope glycoproteins to
infect CD4/CCR5 cells (Figure 4C) and reduced by about 3-fold the infection of CD4/
CXCR4 cells. Thus, the relatively conservative substitution of aspartic acid for asparagine
302 resulted in disruption of CCR5 usage.
Changes in the V3 N-terminus of primary virus envelope glycoproteins
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To investigate the Asn-rich region in the N-terminus of the gp120 V3 region of natural R5
or R5X4 viruses, we introduced changes in residues Asn 300 and Asn 302 of the YU2 (R5)
and 89.6 (R5X4) envelope glycoproteins (Figure 5A). Asn 301 is an N-linked glycosylation
site and the elimination of this glycan could significantly modify the conformation of this
region, so this residue was not altered. The introduction of the changes, N300D and N302D,
alone or in combination, in the dual-tropic 89.6 strain eliminated its infectivity in Cf2Th
cells expressing CD4 and CCR5 or CD4 and CXCR4 (Figure 5B). Similarly, these changes
also eliminated the infectivity of viruses with the YU2 envelope glycoproteins in Cf2Th
cells expressing CD4 and CCR5 (Figure 5B). To examine whether these changes might
affect the integrity of the envelope glycoproteins, we examined the binding of these mutants
to several molecules (Figure 5C). Binding of all the mutants to CD4-Ig and the E51 antibody
was efficient and comparable to that of wild-type 89.6 and YU2 gp120; however, the
binding of mutants N302D and N300D/N302D to the 412d antibody and CCR5 was
drastically reduced, which may have contributed to the lack of infectivity of these mutants in
CD4/CCR5 cells. The N300D change did not affect the binding to the 412d antibody for the
gp120 glycoprotein of either strain. This change significantly reduced the binding of 89.6
gp120 to CCR5, helping to explain the lack of infectivity of this mutant. The YU2 N300D
mutant efficiently binds CCR5 (Figure 5C), even though it does not support infection of
CD4/CCR5 cells (Figure 5B). These results suggested that different mechanisms might
contribute to the loss of infectivity of the 89.6 and YU2 mutants. To investigate this
possibility, we studied the expression, processing and subunit association of these envelope
glycoproteins. Although the expression levels and processing of the mutants were
comparable to those of the wild-type envelope glycoproteins, all the YU2 mutants exhibited
dramatic shedding of gp120 into the medium (Figure 5D). By contrast, the expression,
processing and subunit association of the 89.6 mutants were comparable to those of the
wild-type envelope glycoproteins. These data suggest that the lack of infectivity of the
N300D and N302D YU2 mutants is due to the instability of gp120 association with the
envelope glycoprotein trimer rather than an effect on CCR5-binding ability.
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Many previous studies have demonstrated the role of the HIV-1 gp120 V3 loop in
coreceptor binding and determination of R5 or X4 tropism (Cardozo et al., 2007; Foda,
Harada, and Maeda, 2001; Maeda, Yusa, and Harada, 2008; Sander et al., 2007; Svicher et
al., ; Verrier et al., 1999; Xiao et al., 1998). Here, we addressed how a single V3 structure in
a dual-tropic virus meets the requirements to recognize the CCR5 and CXCR4 coreceptors.
By systematically studying the contribution of V3 loop changes to the generation of an
R5X4 variant, DIΔQR, from the prototypical X4 virus HXBc2, we can suggest a reasonable
mechanistic model for dual tropism.
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First, our studies underscore the critical importance of sequences in the base of the V3 loop
for coreceptor binding. The N-terminus and C-terminus of the V3 loop, which constitute the
V3 base, are quite conserved among X4 and R5 viruses. However, our results show that the
DI motif at residues 325 and 326 in the C-terminal region of the V3 loop is important for
CCR5 utilization as well as for binding to the 412d antibody, but plays a less important role
in CXCR4 usage. The heavy chain complementarity-determining region (CDR) loop of the
412 antibody has sulfate-modified tyrosine residues that mimic the CCR5 N-terminus (Choe
et al., 2003; Dorfman et al., 2006; Huang et al., 2007; Xiang et al., 2005). For example, it
has been shown that these 412d sequences can functionally replace the CCR5 N-terminus to
allow coreceptor function for R5 HIV-1 entry (Xiang et al., 2005). These results suggest that
Asp 325 and Ile 326 might be directly interacting with CCR5, but not with CXCR4.
Although the full structure of CCR5 has not been solved, the NMR structure of a CCR5 Nterminal peptide in the presence or absence of gp120 has been determined and provides
some insight into the interactions between gp120 and the N-terminus of CCR5 (Huang et al.,
2007; Schnur et al., 2011). The docking model of gp120 and the CCR5 N-terminal peptide
(Figure 6A) predicts specific interactions between the N-terminus of CCR5 and the base of
the gp120 V3 loop. In this model, gp120 residues Asn 302, Asp 325 and Ile 326 interact
with Asn 13 and the key sulfated Tyr 10 and Tyr 14 residues in the CCR5 N-terminus. In the
crystal structure of the HIV-1 gp120 core in complex with CD4 and the Fab fragment of the
CCR5-mimetic 412d antibody, the 412d antibody makes similar contacts with the gp120 V3
loop (Huang et al., 2007). The CDR3 loop of the 412d antibody heavy chain crosses over the
base of the gp120 V3 loop and the sulfated tyrosines Tys 100 and Tys 100c of 412d closely
interact with gp120 residues N302, D325 and I326 (Figure 6B). Antibody 412d, however,
interacts with a much larger overall surface of gp120 than the CCR5 N-terminal peptide
(Huang et al., 2007). The additional contacts made by the 412d antibody with gp120
residues conserved among R5 and X4 viruses helps to explain why the HXBc2 DI mutant
efficiently bound the 412d antibody but not CCR5, and thus was unable to infect CD4/CCR5
cells.
Second, our results suggest that additional interactions besides those involving the base of
the gp120 V3 loop are necessary for competent CCR5 attachment. When Gln 310 and Arg
311 were deleted from the V3 tip of the DI mutant, the resulting DIΔQR mutant gained the
ability to use CCR5, exhibiting a typical dual-tropic phenotype. The deletion of residues 310
and 311 was necessary but not sufficient for CCR5 binding and R5 tropism. Apparently, the
presence of Gln 310 and Arg 311 interferes with the interaction of gp120 with CCR5.
Previous studies have suggested that the tip of the V3 loop may contact the second and third
extracellular loops (ECL2 and ECL3) of the coreceptors (Chabot and Broder, 2000; Maeda
et al., 2008; Samson et al., 1997; Wu et al., 1997; Zhang et al., 2007). The proposed twopoint contact involving the base and tip of the gp120 V3 loop with the CCR5 N-terminus
and extracellular loops, respectively, implies that the length and spatial geometry of the V3
loop are both important for efficient CCR5 binding. The QR insertion in the V3 tip could
conceivably alter either of these V3 parameters, disrupting the interaction with CCR5.
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CCR5 and CXCR4 usage might be dictated by different residues within the V3 loop. For R5
tropism, residues 302, 325 and 326 in the V3 base, residues in the V3 tip, and the length and
orientation of the V3 loop are important; for ×4 tropism, other residues like 306, 321 and
322, as previously reported (Cardozo et al., 2007), appear to be important.
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Our previous studies (Xiang et al., 2010) have shown that changes in the length or
orientation of the V3 loop can disrupt the stability of the HIV-1 envelope glycoprotein
trimer. We showed that single amino acid insertions in the V3 loop can destabilize the
envelope glycoprotein trimer, and that the envelope glycoproteins of R5 viruses are more
sensitive than those of ×4 viruses to these insertions (Xiang et al., 2010). Some of the
alterations of the V3 loop studied here affected the stability of the envelope glycoprotein
trimer, resulting in shedding of gp120 and loss of infectivity. The impact of some V3
changes on envelope glycoprotein trimer stability differed in R5, ×4 and R5×4 viruses. For
example, the N302D change resulted in gp120 shedding in the envelope glycoproteins of the
R5 YU2 isolate, but not in the envelope glycoproteins of the ×4 HXBc2 or R5×4 89.6
isolates. In our previous study (Xiang et al., 2010), insertions in the V3 loop of the ×4
HXBc2 isolate did not induce shedding of gp120, whereas the same V3 changes in R5
isolates did. Our results indicate that R5×4 Envs (89.6 or HXBc2 DIΔQR) resemble ×4
Envs with respect to the induction of gp120 shedding by V3 changes. Together, the data
indicate that R5 isolates are more prone to the shedding of gp120 as a result of the
introduction of changes in the V3 loop. In the unliganded HIV-1 envelope glycoprotein
trimer, the V3 loop has been suggested to project towards the trimer axis (Mao et al., 2012;
Xiang et al., 2010). The V3 loops of R5 viruses may be accommodated differently in the
envelope glycoprotein structures that abut the trimer axis than the V3 loops of ×4 and dualtropic viruses.
Our results add to an understanding of the gp120 V3 loop determinants that dictate
coreceptor usage, and provide mechanistic insights into the particular V3 changes involved
in the shift from mono tropism to dual tropism. This understanding may assist attempts to
block the interaction of HIV-1 with its coreceptors.

Materials and Methods
HIV-1 envelope glycoprotein V3 loop mutants
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Mutations were introduced into the pSVIIIenv plasmid expressing the full-length envelope
glycoproteins from the HXBc2 HIV-1 strain (Sullivan et al., 1995), using the QuikChange II
XL site-directed mutagenesis protocol (Stratagene). The presence of the desired mutations
was confirmed by DNA sequencing. The gp120 substitution mutants are designated with the
amino acid residue to the right of the number substituted for the amino acid residue to the
left of the number. All residues are numbered according to those of the prototypic HXBc2
sequence, as per current convention (Korber et al., 1998).
Syncytium formation assay
The ability of the HIV-1 envelope glycoprotein variants to mediate cell-cell fusion was
determined by the α-complementation assay (Holland et al., 2004). In this assay, the Nterminal (α) fragment of β-galactosidase is coexpressed with the HIV-1 envelope
glycoproteins; the C-terminal (ω) fragment of β-galactosidase is expressed in the receptorbearing target cells. Upon fusion of the envelope glycoprotein-expressing cells and the target
cells, the β-galactosidase is reconstituted, and its activity can be measured. The assay was
performed as previously described (Xiang et al., 2010). Briefly, 293T cells in six-well plates
were transfected with plasmids expressing the β-galactosidase fragment, the HIV-1 envelope
glycoproteins and the HIV-1 Tat protein in a 4:4:1 weight ratio. Cf2Th-CD4/CCR5 cells or
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Cf2Th-CD4/CXCR4 cells in 100-mm dishes were transfected with 3 μg of a plasmid
expressing the β-galactosidase ω fragment. On the next day, the Cf2Th target cells were
lifted from the plates with 5 mM EDTA in phosphate-buffered saline (EDTA-PBS) and
reseeded at 105 cells/well in 96-well plates. One day later, the transfected 293T cells were
lifted from the plates with 5 mM EDTA-PBS and diluted to 2 × 105 cells/ml with Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum (DMEM-10).
Approximately 2 × 104 293T cells (in 100 μl) expressing the HIV-1 envelope glycoproteins
were added in triplicate to each well of a 96-well plate containing the target cells. The
cocultivated cells were cultured at 37°C in a CO2 incubator for 4 h. The medium was then
removed, and the cells were washed once with PBS and lysed in 20 μl of lysis buffer. The
plate was covered with Parafilm, wrapped in plastic film and placed at −70°C for 30 min.
The β-galactosidase activity was measured with a Galacto-Star β-galactosidase reporter
gene assay system for mammalian cells (Tropix, Bedford, MA), using a Berthold Microplate
Luminometer LB 96V (Promega).
Infection by single-round luciferase-expressing HIV-1

NIH-PA Author Manuscript

Envelope complementation assays were performed using HIV-1 viruses capable of only a
single round of infection, as described previously (Pacheco et al., 2008). Briefly,
recombinant luciferase-expressing HIV-1 viruses (Helseth et al., 1990) were generated by
transfecting 293T cells with the pSVIIIenv plasmid expressing the HIV-1 envelope
glycoproteins of interest, the pCMVΔP1ΔenvpA packaging plasmid, and an HIV-1 vector
plasmid at a 1:1:3 ratio, using the calcium phosphate transfection method (Invitrogen). The
HIV-1 vector plasmid expresses an RNA that can be packaged into virions, reverse
transcribed, and integrated into a target cell, where it encodes firefly luciferase. Forty-eight
hours after transfection, supernatants containing reporter viruses were harvested and cleared
by low-speed centrifugation. The amounts of virus in the supernatants were assessed by
measurement of reverse transcriptase (RT) (Rho et al., 1981). For infection, Cf2Th-CD4/
CCR5 or Cf2Th-CD4/CXCR4 cells were seeded at a density of 6000 cells/well in 96-well
luminometer-compatible tissue culture plates. The following day, the cells were incubated
with 2,500 RT units of recombinant virus per well. Two days later, the cells were lysed with
30 μl of passive lysis buffer (Promega), and the luciferase activity measured in the Berthold
microplate luminometer LB 96V (Promega).
Immunoprecipitation of HIV-1 envelope glycoproteins
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293T cells were transfected with pSVIIIenv plasmids expressing the HIV-1 envelope
glycoproteins and a plasmid expressing the HIV-1 Tat protein. One day later, the cells were
metabolically labeled for 16 h with 100 μCi/ml of [35S]-methionine/cysteine ([35S] protein
labeling mix; Perkin-Elmer) in Dulbecco's modified Eagle's medium lacking methionine and
cysteine and supplemented with 5% dialyzed fetal bovine serum. The cell lysates
(containing gp160 and gp120) and media (containing gp120) were used for
immunoprecipitation. Briefly, 100 μl of clarified cell lysate or medium was incubated with
100 μl of 10% protein A-Sepharose beads (Amersham Biosciences), 50 μl of 4% bovine
serum albumin, and 1 μg of monoclonal antibody with or without sCD4 (10 μg/ml) or,
instead of the monoclonal antibody, 4 μl of a mixture of sera from HIV-1-infected
individuals. The mixtures were brought to a volume of 1 ml with PBS and incubated on a
shaking platform at room temperature for 1 h. The pelleted beads were washed twice with
0.5 M NaCl-PBS and once with PBS. The beads were then suspended in a 2× gel-loading
buffer, and boiled for 3 min. Following the removal of the beads by centrifugation, the
supernatants were loaded on a 10% SDS-polyacrylamide gel. The gel was fixed, dried at
80°C for 2 hrs and exposed to X-ray film.
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CCR5-binding assay
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To assess CCR5-binding ability, normalized amounts of radiolabeled gp120 envelope
glycoproteins from transfected 293T cell supernatants were incubated with an excess of
sCD4 and Cf2Th-CCR5 cells, as previously described (Xiang et al., 2010). Briefly, Cf2ThCCR5 cells were lifted from the plate by using 5 mM EDTA-PBS (pH 7.5). After a wash
with DMEM, the cells were resuspended in DMEM and added to 1.5-ml microcentrifuge
tubes (106 cells/tube). The radiolabeled gp120-containing cell supernatants (400 μl) and 10
μg of sCD4 were added to the tube, and the volume was adjusted to 1 ml with DMEM. The
tubes were rocked at room temperature for 1 h. The cells were then washed once with PBS
and lysed in 1 ml of buffer containing 1% NP-40. The cell lysates were precipitated with a
mixture of sera from HIV-1-infected individuals and protein A-Sepharose beads (Amersham
Biosciences) at 4°C for 2 h. The precipitated gp120 was analyzed by SDS-PAGE and
autoradiography.
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•

Characterized a dual tropical mutant HIV 1 strain derived from the prototypical
X4 strain HXBc2.

•

Deciphered the molecular interactions between the HIV-1 gp120 V3 loop and
the coreceptors (CCR5 and CXCR4).

•

Distinguished the sequence requirements for CD4-induced antibody 412d and
CCR5 coreceptor binding.

•

Modeled the similar structural basis of 412d antibody and CCR5 coreceptor
interaction with gp120.
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Figure 1.

Sequence alignment of the V3 loops of several common X4-, R5-, and dual-tropic HIV-1
strains. Amino acid position numbering is based on that of the prototypic HXBc2 strain, as
per current recommendations (Korber et al., 1998). Key V3 residues that have been
previously implicated in coreceptor choice are highlighted with stars. Residues conserved
among the V3 loops shown are boxed. A potential N-linked glycosylation site at asparagine
301 is indicated by a black oval.
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Figure 2.
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Sequences and phenotypes of V3 variants of X4 envelope glycoproteins. (A) Sequence
alignment of the V3 loops of the HxBc2 and NL4-3 mutants used in this study. A dot
indicates the same residue and a dash a deletion. The potential N-linked glycosylation site at
asparagine 301 is labeled with a black oval. (B) Infectivity of HXBc2 V3 loop mutants in
cells expressing CD4 and either CXCR4 or CCR5. HIV-1 vectors encoding luciferase and
pseudotyped with the indicated envelope glycoproteins were incubated with cells. Two days
later the cells were lysed and assayed for luciferase activity. The results shown are
representative of those obtained in three independent experiments. The values shown are the
means of four data points from a single experiment and the error bars represent the standard
deviations. (C) Binding of HXBc2 or NL4-3 gp120 mutants with changes in the V3 loop to
the CCR5-mimetic 412d monoclonal antibody. 293T cells expressing the wild-type (wt) or
V3 loop mutant HIV-1 envelope glycoproteins were radiolabeled. The cell supernatants
were precipitated by the 412d monoclonal antibody. The gp120 glycoproteins precipitated
from the media were analyzed by SDS-PAGE and autoradiography. (D) Binding of wt and
mutant gp120 glycoproteins to CCR5. The indicated radiolabeled gp120 envelope
glycoproteins were incubated at room temperature for 1 h with Cf2Th-CCR5 cells in the
presence of sCD4. The cells were washed and lysed, and the bound gp120 was precipitated
by a mixture of sera from HIV-1-infected individuals. The bound gp120 glycoprotein was
analyzed by SDS-PAGE and autoradiography.
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Syncytium-forming activity of HIV-1 envelope glycoprotein variants. 293T cells expressing
the indicated HIV-1 envelope glycoproteins were cocultivated with Cf2Th-CD4/CCR5 cells
and syncytium formation measured as described in Materials and Methods. The values
shown are the means of six data points from a single representative experiment and the error
bars represent the standard deviations.
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Phenotypes of HXBc2 DI△QR envelope glycoproteins with changes in the V3 base. (A)
Binding of ligands to HIV-1 envelope glycoprotein variants. 293T cells expressing wildtype (wt) or V3 loop mutant HIV-1 envelope glycoproteins were radiolabeled. The cell
supernatants were precipitated by a mixture of sera from HIV-1-infected individuals (PS) or
by the indicated monoclonal antibody. The gp120 glycoproteins precipitated from the media
were analyzed by SDS-PAGE and autoradiography. (B) Processing and subunit association
of HIV-1 envelope glycoprotein V3 loop mutants. 293T cells expressing wild-type (wt) or
mutant envelope glycoproteins from the indicated HIV-1 strains were radiolabeled. The cells
were pelleted and lysed. The radiolabeled cell lysates and media were precipitated by a
mixture of sera from HIV-1-infected individuals. The envelope glycoproteins precipitated
from the cell lysates and media were analyzed by SDS-PAGE. The gp160 and gp120
envelope glycoproteins are indicated. (C) Infectivity of HXBc2 V3 loop mutants in cells
expressing CD4 and either CXCR4 or CCR5. HIV-1 vectors encoding luciferase and
pseudotyped with the indicated envelope glycoproteins were incubated with cells. Two days
later the cells were lysed and assayed for luciferase activity. The results shown are
representative of those obtained in two independent experiments. The values shown are the
means of four data points from a single experiment and the error bars represent the standard
deviations.
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Figure 5.
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Effects of changes in the V3 base of primary HIV-1 envelope glycoproteins. (A) Sequence
alignment of the V3 loops of the YU2 and 89.6 envelope glycoprotein mutants used in this
study. A dot indicates the same residue, and a dash indicates a deletion. (B) Infectivity of
YU2 or 89.6 V3 loop mutants in cells expressing CD4 and either CXCR4 or CCR5. HIV-1
vectors encoding luciferase and pseudotyped with the indicated envelope glycoproteins were
incubated with cells. Two days later the cells were lysed and assayed for luciferase activity.
The results shown are representative of those obtained in two independent experiments. The
values shown are the means of four data points from a single experiment and the error bars
represent the standard deviations. (C) Binding of ligands to HIV-1 envelope glycoprotein
variants (previously presented as Supporting Figure S10 in (Huang et al., 2007). 293T cells
expressing the wild-type (wt) or indicated V3 loop mutant HIV-1 envelope glycoproteins
were radiolabeled. The cell supernatants were precipitated by a mixture of sera from HIV-1infected individuals (PS), by CD4-Ig, or by the indicated monoclonal antibody. For some of
the precipitations by the 412d antibody, the gp120-containing cell supernatants were
incubated with sCD4 (final concentration 200 nM). The gp120 glycoproteins precipitated
from the media were analyzed by SDS-PAGE and autoradiography. For the measurement of
CCR5 binding, the indicated radiolabeled gp120 envelope glycoproteins were incubated at
room temperature for 1 h with Cf2Th-CCR5 cells in the presence of sCD4 (200 nM). The
cells were washed and lysed, and the bound gp120 was precipitated by a mixture of sera
from HIV-1-infected individuals. The bound gp120 glycoprotein was analyzed by SDSPAGE and autoradiography. (D) Processing and subunit association of HIV-1 envelope
glycoprotein V3 loop mutants. 293T cells expressing the wild-type (wt) or mutant envelope
glycoproteins from the indicated HIV-1 strains were radiolabeled. The cells were pelleted
and lysed. The radiolabeled cell lysates and media were precipitated by a mixture of sera
from HIV-1-infected individuals. The envelope glycoproteins precipitated from the cell
lysates and media were analyzed by SDS-PAGE. The gp160 and gp120 envelope
glycoproteins are indicated.
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Figure 6.

Models of the interactions of the V3 loop with CCR5 and the 412d antibody. The
interactions of the CCR5 N-terminal domain (A) or the 412d antibody (B) with the V3 loop
of the HIV-1 gp120 envelope glycoprotein were modeled. Residues 302, 325 and 326 in the
base of the gp120 V3 loop and their interaction with the CCR5 N-terminal peptide (A) and
the 412d antibody (B) are shown. The models are based on the NMR structure of CCR52–15
(PDB ID: 2RLL) and the x-ray crystal structure of the gp120-412d-CD4 complex (PDB ID:
2QAD) (Huang et al., 2007).
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